Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM. Kaufmann SH, et al. Among authors: karnitz lm. Haematologica. 2011 Nov;96(11):1619-26. doi: 10.3324/haematol.2011.049551. Epub 2011 Jul 26. Haematologica. 2011. PMID: 21791475 Free PMC article. Clinical Trial.
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT, Heldebrant MP, Vroman BT, Smith BD, Karp JE, Eyck CJ, Erlichman C, Kaufmann SH, Karnitz LM. Mesa RA, et al. Among authors: karnitz lm. Blood. 2005 Jul 1;106(1):318-27. doi: 10.1182/blood-2004-09-3523. Epub 2005 Mar 22. Blood. 2005. PMID: 15784732 Free PMC article.
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P. Hendrickson AE, et al. Among authors: karnitz lm. Gynecol Oncol. 2012 Feb;124(2):210-5. doi: 10.1016/j.ygyno.2011.10.002. Epub 2011 Nov 1. Gynecol Oncol. 2012. PMID: 22047770 Free PMC article. Clinical Trial.
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
Webster JA, Tibes R, Morris L, Blackford AL, Litzow M, Patnaik M, Rosner GL, Gojo I, Kinders R, Wang L, Doyle LA, Huntoon CJ, Karnitz LM, Kaufmann SH, Karp JE, Smith BD. Webster JA, et al. Among authors: karnitz lm. Leuk Res. 2017 Oct;61:108-116. doi: 10.1016/j.leukres.2017.09.005. Epub 2017 Sep 20. Leuk Res. 2017. PMID: 28957699 Free PMC article. Clinical Trial.
The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons.
Flatten K, Dai NT, Vroman BT, Loegering D, Erlichman C, Karnitz LM, Kaufmann SH. Flatten K, et al. Among authors: karnitz lm. J Biol Chem. 2005 Apr 8;280(14):14349-55. doi: 10.1074/jbc.M411890200. Epub 2005 Feb 7. J Biol Chem. 2005. PMID: 15699047 Free article.
Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines.
Gálvez-Peralta M, Dai NT, Loegering DA, Flatten KS, Safgren SL, Wagner JM, Ames MM, Karnitz LM, Kaufmann SH. Gálvez-Peralta M, et al. Among authors: karnitz lm. Mol Pharmacol. 2008 Sep;74(3):724-35. doi: 10.1124/mol.108.047787. Epub 2008 May 28. Mol Pharmacol. 2008. PMID: 18509065 Free PMC article.
85 results